Senhwa Biosciences Presents Clinical Data Abstract on Pidnarulex at 2024 ESMO Congress
The study involved end-stage oncology patients with no other suitable treatment options.
In this Phase Ib study, Pidnarulex (CX-5461) demonstrated acceptable clinical tolerability and showed preliminary signs of efficacy, even in p… อ่านเพิ่ม